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The study demonstrated silymarin nephroprotective activity recommending its potential benefits for the treatment of kidney 
injuries.
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Introduction: Diclofenac (DIC), a phenylacetic acid compound which belongs to nonsteroidal 
anti-inflammatory drugs (NSAIDs), is generally used for the treatment of various diseases 
such as rheumatoid arthritis, ankylosing spondylitis, acute muscle pain conditions and 
osteoarthritis. Overdose of DIC can lead to renal injuries in both experimental animal and 
human. Our research was done to assess the protective role of silymarin on renal damage 
induced by DIC in rats.
Methods: Thirty-two Wistar rats were assigned to four groups (n=8/group). Group 1 was 
control group; animals in group 2 were administrated DIC; Groups 3 and 4 administrated 
DIC plus silymarin with doses of 100 mg/kg and 200 mg/kg, orally (p.o), respectively. Various 
biochemical, molecular, and histological parameters were evaluated in serum and tissue 
homogenate.
Results: In the second group, the levels of kidney catalase (CAT), vitamin C and superoxide 
dismutase (SOD) remarkably reduced (P < 0.05) relative to the control group. Also, urea, 
creatinine (Cr), malondialdehyde (MDA), serum tumor necrosis factor-α (TNF-α) and gene 
expression of TNF-α in this group were noticeably elevated (P < 0.05) relative to the control 
group. Treatment with silymarin caused a remarkable elevation (P < 0.05) in vitamin C, SOD, 
CAT and a remarkable reduction (P < 0.05) in the content of MDA, urea, Cr, TNF-α gene 
expression and serum TNF-α in comparison with second group. Histological injuries were 
also ameliorated by silymarin administration.
Conclusion: The results confirm that silymarin has an ameliorative role against renal damage 
and oxidative stress induced by DIC in male rats.
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A B S T R A C T
Introduction
Usually, a mixture of biochemical and physiological 
phenomena play a role in kidney susceptibility and 
renal toxicity. The kidney is highly sensitive to chemical 
poisoning,  compared to other organs, partly due to its 
unequally high blood flow, and because of its complexity 
both functionally and anatomically. This organ also plays 
an important role in regulation of blood pressure. Urine 
is the main pathway that most of the poisons are repelled. 
Eventually, nephrons condense poisons in the filtration and 
transport those across the tubular cells (1). Nonsteroidal 
anti-inflammatory drugs (NSAIDs) are variety of 
chemical drugs that have similar attributes and are applied 
for control of inflammation and pain. The normal doses 
of NSAIDs only cause gastrointestinal incompatibility. 
However, consumption of high doses of these drugs (such 
as: ibuprofen, diclofenac [DIC], and naproxen) can lead 
to toxicity (2,3). DIC is the most common NSAID used to 
decrease inflammation and arthritis-associated pain (4,5). 
It is absorbed quickly and completely after consumption 
and attaches to albumin in plasma (6).  Gastrointestinal 
side effects are the most common abnormal complications 
of DIC, although nephrotoxicity and liver toxicity are also 
related to DIC intoxication (7,8). All of these characteristics 
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make the kidneys highly susceptible to various types of 
abnormalities.
Silymarin, a flavonoid compound, is derivated 
from Silybum marianum seeds. It is a combination of 
silydianine, silychristine, isosilybinin and silibinin. 
Silymarin creates a protective role in liver because of its 
radical scavenger effects (9). Silymarin has antioxidant 
properties and stabilizes cell membranes and also regulates 
the intracellular GSH (reduced glutathione) and chelates 
metal (copper and iron) ions (10,11). There are many 
pharmacological agents which are associated with renal 
injury. Preventing renal toxicity with use of inexpensive 
and useful drugs reduces hospitalization expenditure, 
also extenuate the rates of morbidity and mortality. To 
the best of our information, there are not investigations 
concerning the renal protective role of silymarin on 
intoxication of DIC. Accordingly, this research was aimed 
to assess the noxious effect of acute DIC intoxication on 
the kidney through evaluation of serum biochemical 
markers, oxidative stress, gene expression of tumor 
necrosis factor-α (TNF-α) and histological alterations.
Materials and Methods
Chemicals
Chemicals such as 2-thiobarbituric acid, sodium acetate, 
and H2O2 were prepared from Merck (Darmstadt, 
Germany). TPTZ (2,4,6-tripyridyl-s-triazine), silymarin 
and nitro blue tetrazolium were purchased from Sigma-
Aldrich (St. Louis, MO). SYBR Green Real-Time PCR 
Master Mix was provided from Qiagen Co. (Dusseldorf, 
Germany). Urea and creatinine (Cr) were measured using 
Pars Azmun Company (Tehran, Iran). All other chemicals 
which employed in this study were of analytical grade.
Animals
Thirty-two male Wistar rats weighting around 200 ± 20 
g (6–8 weeks old) were obtained from Jondi-Shapour 
University (Ahwaz, Iran). The animals were kept in 
standard condition (temperature 23 ± 2°C, free access 
to water and food, and a 12:12 h light– dark cycle) and 
housed four per cage. The rats were accustomed for 7 days 
before the initiation of the experiment. 
Experimental design
The rats were divided randomly into four groups each 
comprising of eight animals. Group 1, control group, was 
treated with normal saline (1 ml/kg body weight (bw), 
i.p.) and 0.5 mL distilled water as the solvent of silymarin 
by gavage an hour later for 5 days to provide equal shock 
in the control group as opposed to other groups. Group 2 
received DIC only (50 mg/kg bw, i.p.) and 0.5 mL distilled 
water as solvent of silymarin by gavage an hour later for 
5 days to provide equal shock in the control group as 
opposed to other groups (12,13). Group 3 received DIC 
(50 mg/kg bw, i.p.) plus silymarin (100 mg/kg bw, p.o) an 
hour later for 5 days (12-15). Group 4 received DIC (50 
mg/kg bw, i.p.) plus silymarin (200 mg/kg bw, p.o) an hour 
later for 5 days (12,16). At the end of the study, the fasted 
rats were sacrificed under mild chloroform anesthesia. 
Whole blood samples were collected by cardiac puncture 
method. The serum and plasma were prepared at 2000 
RPM for 10 minutes. Also, kidney tissue was harvested 
for determining kidney catalase (CAT) and superoxide 
dismutase (SOD) activities, expression of TNF-α gene and 
histological studies. 
Biochemical analysis
Serum urea and Cr levels were measured by an enzymatic 
method (Pars Azmun kit, Pars Azmun Company, Tehran, 
Iran) using autoanalyzer (BT 3000, Biotecnica, Cergy 
Pontoise Cedex, France). Serum TNF-α was assessed using 
the ELISA assay kit (BT-Laboratory, China) according to 
the procedure provided by the manufacturer.
Determination of plasma antioxidant capacity 
Ferric reducing/antioxidant power (FRAP) was 
determined by Heidarian and Soofiniya procedure using 
tripyridyl-triazine (17).
Determination of kidney vitamin C 
Renal tissue level of vitamin C was determined by 
2,4-dinitrophenylhydrazine as describe by Omaye et al 
(18). 
Estimation of lipid peroxidation (MDA) 
Thiobarbituric acid as reagent was used to determine 
serum and renal malondialdehyde (MDA) which formed a 
pink complex with MDA as reported in details previously 
(17).
Determination of tissue CAT and SOD activities
The kidney CAT activity of experimental groups was 
measured as reported in details previously (19). The 
activity of renal SOD was evaluated using the inhibition 
of the NBT photo chemical reaction at 560 nm (20). All 
total protein samples were assessed using the method of 
Bradford (21).
Assessment of kidney TNF-α gene expression
Gene expression of TNF-α on the kidney experimental 
groups was assessed as described previously (22). β-actin 
was used as a housekeeping gene for normalizing the data. 
Histopathological study
A segment of each kidney was fixed in 20% formalin 
solution. All samples were embedded in paraffin and 5 µm 
thickness sections were prepared. Then, the slices stained 
with hematoxylin–eosin (H & E) for histopathological 
observation (23). 
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Statistical analysis
One-way analysis of variance (ANOVA) was used for data 
analysis using SPSS software (Statistical Package for the 
Social Sciences, version 20.0, SPSS Inc, Chicago, IL). All 
data were expressed as mean ± SD. Also, DDCT method 
was used for analysis of TNF-α gene expression. Mean 
values of the groups were compared using the Tukey post 
hoc test. P < 0.05 was statistically considered significant.
Results
Effects of silymarin on serum urea and creatinine
The effects of DIC and silymarin on serum Cr and urea 
are shown in Table 1. In group 2, administration of DIC 
led to a noticeable elevation (P < 0.05) in serum Cr and 
urea relative to the normal group (Table 1). However, 
in groups 3 and 4, administration of silymarin resulted 
in a remarkable decline (P < 0.05) in serum Cr and urea 
relative to the second group.
Effects of silymarin on MDA levels and plasma FRAP
The effects of Silymarin on plasma FRAP, tissue MDA 
and serum MDA levels are shown in Table 2. In group 2 
(DIC-only treated group), administration of DIC resulted 
in a noticeable decrease (P < 0.05) in plasma FRAP and 
an increase in tissue and serum MDA levels relative to 
the normal group (group 1). Treatment with silymarin 
in groups 3 and 4 caused a remarkable increase (P < 0.05) 
in plasma antioxidant capacity and a significant decrease 
(P < 0.05) in tissue and serum MDA levels relative to 
second group. Also, a remarkable alteration (P < 0.05) 
was seen in plasma FRAP, serum MDA and renal MDA 
between the third (silymarin-treated group with 100 mg/
kg) and fourth (silymarin-treated group with 200 mg/kg) 
groups.
Effects of silymarin on CAT activity, SOD activity and 
vitamin C level
Table 3 shows that injection of DIC led to a noticeable 
reduction (P < 0.05) in renal CAT activity in second group 
(DIC-only group) relative to the normal group (group 1). 
A considerable increase (P < 0.05) in kidney CAT activity 
was observed in silymarin-treated groups relative to the 
second group (DIC-only group). Table 3 also shows a 
remarkable decrease (P < 0.05) in renal SOD activity in the 
second group (DIC-only treated group) when compared 
with the control group. However, administration of 
silymarin in third and fourth groups caused a significant 
elevation (P < 0.05) in renal SOD activity relative to the 
second group. Also injection of DIC in DIC-only treated 
group (group 2) led to a noticeable reduction (P < 0.05) in 
kidney vitamin C relative to the normal group (Table3). 
However, in groups treated with doses of 100 and 200 
mg/kg silymarin (groups 3 and 4), kidney vitamin C 
remarkably elevated (P < 0.05) relative to the DIC-only 
treated group (group 2).
The effects of silymarin on serum and gene expression of 
TNF-α
The effects of silymarin on serum content of TNF-α 
and TNF-α gene expression are shown in Figure 1. DIC 
injection in group 2 led to a remarkable elevation (P < 0.05) 
in serum content of TNF-α and TNF-α gene expression 
relative to the normal group (group 1). On the other hand, 
treatment with silymarin caused a remarkable decrease 
(P < 0.05) in serum content of TNF-α and TNF-α gene 
expression relative to the second group (DIC-only treated 
group). A noticeable change (P < 0.05) was seen in serum 
content of TNF-α and TNF-α gene expression in the third 
group (treated with doses of 100 mg/kg silymarin) relative 
Table 1. Effect of silymarin on serum urea and creatinine
Parameters (mg/dL) Group 1 Group 2 Group 3 Group 4
Urea 29.85 ± 2.36 54.25 ± 3.53a 36.86 ± 2.98ab 28.69 ± 2.49bc
Creatinine 0.81 ± 0.09 1.88 ± 0.18a 0.91 ± 0.1b 0.79 ± 0.11b
Data are expressed as mean ± SEM (n=8) and analyzed by one-way ANOVA followed by Tukey post hoc test. Group 1: normal group; group 2: diclofenac 
only; groups 3 and 4 were treated by diclofenac plus silymarin with doses of 100 mg/kg and 200 mg/kg, respectively.
a P < 0.05 versus control group (group 1).
b P < 0.05 versus diclofenac administered group (group 2).
c P < 0.05 versus group treated with 100 mg/kg silymarin (group 3).
Table 2. Effect of silymarin on ferric reducing/antioxidant power (FRAP) and malondialdehyde (MDA) levels in the experimental groups
Parameters Group 1 Group 2 Group 3 Group 4
Serum FRAP (μM) 526.27 ± 31.22 374.26 ± 27.41a 498± 37.64b 612.25 ± 48.66abc
Serum MDA (μM) 8.43 ± 2.52 19.68 ± 3.18a 13.65 ± 2.15ab 8.17 ± 1.87bc
Renal MDA (μmol/mg protein) 1.91 ± 0.71 5.51± 1.15a 3.56 ± 0.76ab 1.87 ± 0.58bc
Data are expressed as mean ± SEM (n=8) and analyzed by one-way ANOVA followed by Tukey post hoc test. Group 1: normal group; group 2: diclofenac 
only; groups 3 and 4 were treated by diclofenac plus silymarin with doses of 100 mg/kg and 200 mg/kg, respectively.
a P < 0.05 versus control group (group 1).
b P < 0.05 versus diclofenac administered group (group 2).
c P < 0.05 versus group treated with 100 mg/kg silymarin (group 3).
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to the fourth group (treated with doses of 200 mg/kg 
silymarin).
Histopathological findings
The histological results of kidney from the experimental 
groups are demonstrated in Figure 2. The microscopic 
examination depicted normal structures of kidney 
tissue from a normal rat in control group (Figure 
2A). Administration of DIC-only in group 2 showed 
mononuclear cells filtration and histological changes 
compared to the control group that reflected renal damage 
(Figure 2B). The decrease of inflammatory cell infiltration 
was observed in silymarin-treated groups (Figure 2C-D) 
relative to the second group (DIC-only treated group). 
The decrease of inflammatory cells in the fourth group 
(silymarin-treated group with dose of 200 mg/kg) was 
more than the third group (silymarin-treated group with 
dose of 100 mg/kg).
Discussion
About 60% of hospital-acquired acute kidney injury is due 
to drug-induced nephrotoxicity, which is a main reason 
of morbidity and mortality. Multiple factors, such as 
dose regulation based on renal function, hydration and 
avoidance of nephrotoxic agents, have been suggested to 
prevent or improve drug-induced nephrotoxicity (24,25). 
Nevertheless, drug induced toxicity remains a major 
problem for health care specialists. Therefore, finding 
impressive approaches to reduce renal injuries are of notable 
importance. Silymarin is widely used as a hepatoprotective 
medication. Anti-inflammatory and antioxidant actions, 
deterrence of lipid peroxidation, protein synthesis 
induction, neutrophil migration and leukotriene and 
prostaglandin synthesis are pharmacologically depicted 
effects of silymarin bioflavonoids (26-28). Silymarin may 
show positive effects in the management of patients with 
renal injuries.
Our findings that DIC causes acute renal injury 
manifested as significant urea and Cr elevations. In 
our research, kidney histological findings depicted 
that injection of DIC caused renal damage (Figure 2) 
accompanied with elevates in serum urea and Cr (Table 
1). Same results were reported in prior reports (29,30). 
It is generally accepted that the toxicity of DIC is 
strongly associated with oxidative stress leading to lipid 
peroxidation and injury to the cellular macromolecules 
(7,31). In groups 3 and 4 DIC-induced deteriorations 
reduced by silymarin treatment which are in agreement 
with prior investigations (32,33). On the other hand, 
this renal protective effect of silymarin may be due to 
its stabilizing effects on plasma membrane and proteins 
against reactive oxygen species (ROS).
In our research, the injection of DIC not only led to a 
remarkable reduction in activities of SOD and CAT but also 
Table 3. Effect of silymarin on catalase (CAT) activity, superoxide dismutase (SOD) activity and vitamin C level in the experimental groups
Parameters Group 1 Group 2 Group 3 Group 4
CAT (U/mg protein) 165.32± 14.32 55.27±6.12a 112.87±9.76ab 167±15.13bc
SOD (U/mg protein) 46.32± 4.12 27.61±2.89a 37.21±3.13ab 47.43±3.98bc
Vitamin C (mg/g of wet kidney) 15.45±2.12 8.87± 1.12a 12.78± 1.76b 15.88±2.68b
Data are expressed as mean ± SEM (n=8) and analyzed by one-way ANOVA followed by Tukey post hoc test. Group 1: normal group; group 2: diclofenac 
only; groups 3 and 4 were treated by diclofenac plus silymarin with doses of 100 mg/kg and 200 mg/kg, respectively.
a P < 0.05 versus control group (group 1).
b P < 0.05 versus diclofenac administered group (group 2).
c P < 0.05 versus group treated with 100 mg/kg silymarin (group 3).
Figure 1. Effect of silymarin on serum tumor necrosis factor-α (TNF-α) and expression of TNF-α. Each value represents the mean ± SEM of eight rats. Group 
1: normal group; group 2: diclofenac only; groups 3 and 4 were treated by diclofenac plus silymarin with doses of 100 mg/kg and 200 mg/kg, respectively.
a P < 0.05 versus control group (group 1).
b P < 0.05 versus diclofenac administered group (group 2).
c P < 0.05 versus group treated with 100 mg/kg silymarin (group 3).
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caused a notable increase in MDA contents relative to the 
normal group. This can be due to the formation of surplus 
free radicals produced by metabolites of DIC that defeat 
the antioxidant system and result in lipids peroxidation. 
These results are in line with prior investigations (22,34). 
The administration of silymarin in third and fourth 
groups causes a noticeable elevation in activities of SOD 
and CAT relative to those rats in second group (DIC-only 
treated group). Silymarin has antioxidant properties and 
stabilizes the membrane (27,35). The noticeable increase 
in CAT and SOD activities and decrease in MDA contents 
of the animals treated with 100 and 200 mg/kg doses of 
silymarin (groups 3 and 4) demonstrate the decrease of 
free radicals. Also, histopathological studies depicted 
that mononuclear cells infiltration was reduced in treated 
rats with 100 and 200 mg/kg doses of silymarin (groups 
3 and 4) (Figure 2). Thus, it is indicated that silymarin 
severely scavenges free radicals and stabilizes renal cell 
membrane by removing poisonous oxidative species via 
detoxification system of body, thereby protecting the 
kidney tissues from injury. Furthermore, in our research 
treatment with silymarin in groups 2 and 3 caused a 
remarkable elevation in levels of plasma FRAP (Table 2) 
that approved antioxidant properties of silymarin and can 
be considered as a reason for elevation of CAT and SOD 
and reduction of MDA in silymarin-treated groups.
Vitamin C is responsible for destroying and scavenging 
free radicals as a non-enzymatic antioxidant (36). It 
inhibits the release of free radicals which can prevent 
primary and secondary oxidation of nucleic acids, 
proteins and lipids (37). The reduced content of ascorbic 
acid in DIC treated animals (group 1) may be because 
Figure 2. Effects of Silymarin on the renal histopathology of experimental 
groups. (A) Control group with normal structure; (B) diclofenac-injected 
rats without treatment show lymphocyte infiltration (the black arrows); (C) 
diclofenac-injected rats supplemented with silymarin (100 mg/kg bw); (D) 
diclofenac-injected rats supplemented with silymarin (200 mg/kg bw).
A
C D
B of the elevated usage as an antioxidant defense against 
elevated ROS or reduction of glutathione content, since 
glutathione is needed for the recycling of vitamin C (38). 
However, administration of silymarin increased vitamin 
C in the treated groups compared with its level in group 2 
(administration DIC only) which is in agreement with the 
findings of previous studies (22,39,40). Thus, the increase 
of vitamin C can be considered a reason for reducing ROS 
in silymarin-treated groups and the recuperation of renal 
damage and morphological changes. 
Inflammatory cytokines and chemokines play a main 
role in nephrotoxicity induced by DIC (41). TNF-α is a 
cytokine which releases the inflammatory conditions and 
migration of macrophages. TNF-α leads to oxidative stress 
which in turn increases the renal cells damage. Previous 
findings also demonstrated that TNF-α gene expression 
was elevated in renal damages (22,42-44). In our research, 
there was a noticeable elevation in both serum level 
and renal expression of TNF-α in the animals of second 
group (DIC- only treated group) compared to the normal 
group (Figure 1). Also histopathological examinations 
confirmed inflammation in kidney tissues of DIC-treated 
rats (Figure 2). Nevertheless, oral injection of silymarin at 
doses of 100 or 200 mg/kg after treatment with DIC led to a 
remarkable reduction in the levels of this parameter which 
is in agreement with histopathological findings in these 
groups. Thus, the decrease in levels of serum TNF-α and 
expression of TNF-α gene is an acceptable evidence that 
confirms the nephroprotective role of silymarin because 
of its antioxidant properties. Accordingly, because of the 
growing trend in the use of NSAIDs around the world, we 
offer that future investigations focusing on the probable 
roles of silymarin on the injury induced by DIC on other 
vital organs.
Conclusion
In conclusion, our research approved the protective role 
of silymarin against renal damage induced by diclofenac 
in rats because not only it decreases renal inflammatory 
cells, lipid peroxidation and TNF-α, but also elevates 
kidney activities of vitamin C, CAT, and SOD. 
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